Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2-Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical Study. This evidence concerns the gene ERBB2 and breast cancer.